Full name: Dr. Luong Xuan Huy
Position: Lecturer
Belongs to the unit: Department of Chemical Engineering
Email address: huy.luongxuan@hust.edu.vn
Specialized group: Pharmaceutical, Cosmetic and Pesticide Chemical Engineering.
| Year | Degree | Academic Institution |
| 2020 | Doctor | Dongguk University, Korea |
| 2016 | Master | Dongguk University, Korea |
| 2014 | Pharmacist | Hanoi University of Pharmacy, Vietnam |
| Time | Position | Organization |
| 2026-now | Lecturer | Hanoi University of Science and Technology, Vietnam |
| 2024-2026 | Research Professor | Yeungnam University, Korea. |
| 2020-2026 | Lecturer | Phenikaa University, Vietnam. |
| Course ID | Course name | Program |
| CH4517E | Structure-activity relationships | ELITECH program of Pharmaceutical chemical engineering |
| CH5614 | Medicinal Chemistry Project | Kỹ thuật Hóa học |
| CH4516E | Seminar | ELITECH program of Pharmaceutical chemical engineering |
| CH4502E | Research Project | ELITECH program of Pharmaceutical chemical engineering |
| Type of project | Name of project | Role | Time frame | ||||
| NAFOSTED | Synthesis and optimization of peptides from coconut water Cocos nucifera with potential to treat antibacterial and antifungal infections | Principle investigator | 2023-2026 | ||||
| Phenikaa Group | Laboratory-Scale Synthesis of the Commercial Peptides AH-8 and Leuprorelin Acetate | Principle investigator | 2022-2023 | ||||
| Phenikaa University | Development of a Laboratory-Scale Chemical Synthesis Process for Antimicrobial Peptides | Principle investigator | 2020-2021 | ||||
| NAFOSTED | Development of Cationic Amphiphilic Antimicrobial Agents | Scientific Secretary | 2024-2027 | ||||
| NAFOSTED | Synthesis and Evaluation of the Antibacterial and Anticancer Activities of Natural Lasioglossin-III Peptide Derivatives | Key Member | 2025-2028 | ||||
| NAFOSTED | Peptide-Based Therapy for Prostate Cancer: From In Vitro research to Personalized Treatment Strategies Using Organoid Models | Key Member | 2025-2028 | ||||
| NAFOSTED | Development of Standardized Soybean-Derived Peptides for the Treatment of Dyslipidemia | Key Member | 2025-2028 | ||||